Clonazepam (Klonopin): Uses, Risks, Dependence, and What to Expect

Clonazepam (brand name: Klonopin) is a benzodiazepine (long-acting). Clonazepam enhances the effect of gamma-aminobutyric acid (GABA), the brain's primary inhibitory neurotransmitter, by binding to GABA-A receptors and increasing the frequency of chloride channel opening. This produces anxiolytic, anticonvulsant, sedative, and muscle relaxant effects. Clonazepam has a long half-life (18-50 hours) compared to other benzodiazepines, which provides more stable blood levels and longer duration of action.

• Panic Disorder (with or without agoraphobia)
• Seizure disorders (Lennox-Gastaut syndrome, absence seizures, myoclonic seizures)

Common off-label uses:

• Generalized Anxiety Disorder
• Social Anxiety Disorder
• Restless Legs Syndrome
• REM Sleep Behavior Disorder
• Acute mania (adjunctive)
• Akathisia
• Catatonia

Panic disorder: start 0.25 mg twice daily, increase by 0.25-0.5 mg every 3 days to 1-2 mg/day. Maximum 4 mg/day. Seizures: 1.5 mg/day in 3 divided doses, up to 20 mg/day. Elderly: start at lower doses (0.25 mg). Available as tablets and orally disintegrating tablets.

Anxiolytic effects begin within 30-60 minutes. Peak plasma levels at 1-4 hours. Due to long half-life, steady-state takes 5-7 days.

• Drowsiness and sedation
• Dizziness
• Impaired coordination and balance
• Cognitive impairment (memory, attention)
• Depression or worsening of depression
• Fatigue

• Physical dependence (develops in weeks to months of regular use)
• Severe withdrawal (seizures, psychosis, death if stopped abruptly after prolonged use)
• Respiratory depression (especially when combined with opioids — FDA black box warning)
• Paradoxical reactions (agitation, aggression, disinhibition)
• Increased fall risk in elderly
• Cognitive decline with long-term use

Dangerous combinations with opioids (respiratory depression — FDA black box warning), alcohol, and other CNS depressants. CYP3A4 substrate — levels increased by ketoconazole, fluconazole. Levels decreased by carbamazepine, phenytoin.

Category D — associated with increased risk of oral cleft and other malformations. Neonatal withdrawal syndrome ('floppy infant syndrome') with late-pregnancy use. Generally avoided during pregnancy.

NEVER stop abruptly after regular use. Taper very gradually — typically 0.125 mg reduction every 1-2 weeks, slower if needed. Some tapers take 6-12 months. Withdrawal symptoms include seizures, psychosis, severe anxiety, insomnia, tremor, and perceptual disturbances. Benzodiazepine withdrawal can be life-threatening.